# Classification of driver and passenger mutations in different cancer types using deep neural networks

## TL;DR

This study uses deep learning to classify driver and passenger mutations in 30 cancer types, improving accuracy with structural data from AlphaFold.

## Contribution

A novel deep learning method integrating AlphaFold structures to distinguish driver from passenger mutations in cancer.

## Key findings

- Motif-based preferences and structural features improve driver mutation classification.
- The model achieved 84.06% accuracy using 10-fold cross-validation.
- AlphaFold integration enhanced pathogenicity prediction of mutations.

## Abstract

Cancer is driven by genetic changes, known as mutations, that lead to the uncontrolled division of cells. The functional significance of a vast number of these cancer somatic mutations is unknown, and it is one of the major challenges in cancer research. In this study, we performed an integrative analysis of 30 tumor types from PAN-cancer mutation data collected from the COSMIC database. We have analyzed a set of 61 364 missense mutations (57 535 drivers and 3829 passengers) from 682 cancer-causing genes and derived various important features from amino acid sequences, predicted AlphaFold structures, and amino acid contact networks. We observed that the motif-based preference, neighboring residue information, residue depth, and disorder regions around the site of mutation are important for the discrimination of drivers and passengers.

We further developed cancer-specific computational models to discriminate cancer-causing and passenger mutations using deep learning, and the integration of AlphaFold predicted structure information improved the pathogenicity prediction of mutations. Our method achieved an average classification accuracy of 84.06% with 10-fold cross-validation.

The prediction server is available at https://web.iitm.ac.in/bioinfo2/PANDriver/index.html. We envisage that the AI-based prediction models would be an important tool to identify driver mutations and could extend the scope of precision medicine for cancer.